Monogram Biosciences Release: Data Highlighting The Role Of Molecular Diagnostics Presented At Major HIV/AIDS Meeting
SOUTH SAN FRANCISCO, Calif., Feb. 9 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. today announced the presentation of over 25 abstracts related to its portfolio of HIV resistance assays at the 13th Annual Conference on Retroviruses and Opportunistic Infections (CROI). Data presented at the conference support the utility of Monogram's assays in predicting viral susceptibility to a wide variety of approved and investigational antiretroviral drugs and vaccines. These data join a growing body of evidence that stresses the critical role that molecular diagnostics plays in advancing personalized treatment for HIV.
"The number and diversity of abstracts related to Monogram's HIV assays reflect the value that our diagnostics bring to the development and use of HIV therapies," said William Young, CEO of Monogram. "Given the proliferation of HIV therapies in the market and under development, the task of matching patient and drug has become all the more difficult. Our assays provide a comprehensive picture that helps assess viral vulnerability and guide treatment."
The abstracts describe the use of Monogram's PhenoSense GT(TM) resistance assay, PhenoSense(TM) Entry assay which evaluates susceptibility to all entry inhibitors, and HIV Co-Receptor Tropism assays in a variety of settings, including:
* Evaluation of HIV resistance to currently approved drugs * Evaluation of resistance and co-receptor usage related to approved and investigational entry inhibitors * Development of novel drug compounds * Exploration of the role of neutralizing antibody responses in refining treatment strategies and developing HIV vaccines * Analysis of replication capacity as a predictor of clinical outcome
With over 20 approved HIV drugs, 60 more in development and a countless number of possible drug combinations, there is a real need for tools to help select the appropriate treatment regimens for patients. Monogram's proprietary technology has been used during the development of every HIV drug approved by the FDA in the past five years. The company has active collaborations with almost all of the major pharmaceutical companies that are developing HIV drugs, including Pfizer, GSK and Schering Plough.
"In the past ten years, HIV therapeutics and diagnostics have matured to generate many enhanced treatment options, including a number of expensive, highly selective therapies. Knowing how an individual's expression of the disease will respond is critical to preserving treatment options and saving precious time and resources," said Young.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.
Forward-Looking Statements
Certain statements in this press release and attached supplemental information are forward-looking. These forward-looking statements include references to the potential use for the Company's tests in early access programs as well as in commercial use of CCR5 entry inhibitor drugs if approved by the FDA, and the potential impact of the Contingent Value Rights. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any CCR5 clinical trials; the use of our Co-receptor Tropism assay for patient use in the event of approval of any CCR5 inhibitors; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payors will authorize reimbursement for our products and services; whether the FDA or any other agency will decide to further regulate our products or services; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; the potential impact of cash and/or stock payments by us on the Contingent Value Rights issued to shareholders of ACLARA; and whether we will be able to raise sufficient capital if required. For a discussion of other factors that may cause our actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.
PhenoSense is a trademark of Monogram Biosciences, Inc. Contacts: Alfred G. Merriweather Jeremiah Hall Chief Financial Officer Feinstein Kean Healthcare Tel: 650 624 4576 Tel: 415 677-2700 amerriweather@monogrambio.comjeremiah.hall@fkhealth.com
Monogram Biosciences, Inc.CONTACT: Alfred G. Merriweather, Chief Financial Officer of MonogramBiosciences, Inc., +1-650-624-4576, amerriweather@monogrambio.com; orJeremiah Hall of Feinstein Kean Healthcare, +1-415-677-2700,jeremiah.hall@fkhealth.com
Web site: http://www.monogrambio.com/